13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

26
13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul Lung Volume Reduction Surgery Walter Weder MD Professor of Surgery University Hospital Zurich

description

Lung Volume Reduction Surgery. 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul. Walter Weder MD Professor of Surgery University Hospital Zurich. COPD Function – Symptoms - HRQL. HRQL. FEV 1. RV/TLC. Chest wall Mechanics. DLCO. Physical Performance. Heart. - PowerPoint PPT Presentation

Transcript of 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Page 1: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

13. Annual Congress Turkish Thoracic Society

5. – 9. May 2010, Istanbul

Lung Volume Reduction Surgery

Walter Weder MDProfessor of Surgery

University Hospital Zurich

Page 2: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

COPDFunction – Symptoms - HRQL

DyspneaDyspnea

PhysicalPerformance

PhysicalPerformance

HRQLHRQL

HeartHeart

MusclesMuscles

FEV1FEV1

RV/TLCRV/TLC

DLCODLCO

GasexchangeGasexchange

PulmonaryCirculationPulmonaryCirculation

Chest wall MechanicsChest wall Mechanics

Page 3: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

LVRS for emphysema

Page 4: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

•Resection planned by chest CT Morphology („target areas“)

•Thorascopic wedge-resection (endoscop. linear stapler) of most impaired areas

•Usually bilateral procedure

•Smoker‘s emphysema: „hockey stick“ Resection of the upper lobe

•Lower lobe (a1-AT-deficiency): Resection of basal LL segments

Surgical Technique

Page 5: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul
Page 6: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Emphysema Morphology

Page 7: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Effect on FEV1 and Dyspnea

LVRS: Effect on FEV1 (% predicted)

LVRS: Effect on Dyspnea

Weder, Ann Thorac Surg 2006

Page 8: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Single center studies on LVRS

Author nSurgical Mortality

FEV16 Month Duratio

nRemarks

Ciccone 2003250

4,8 % + 73 % > 5y upper lobes

Weder 2005212

2.4 % + 41 % > 5y all morphologies

Senbaklavaci 1999

91 5,5 % + 28 % diff. techniques

Brenner 2000237

+ 69 % > 2y no info

Flaherty 2001 98 5,6 + ± 50 % > 3y upper lobes

Page 9: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Randomized studies on LVRS

Autor n

Surg.

Mort. Result

Geddes, 2000 48 6 % FEV1 , HRQL

Pompeo, 2000 60 6,6 % Pulmonary function

Hillerdal, 2005 106 12 % can improve health status

Miller, 2006 62 0 / 6 % FEV1 , HRQL

Page 10: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

The NETTNational Emphysema

Treatment TrialRationalLVRS did historically not provide convincing evidence for efficacy or reliable characterization of a subset of patients likely to benefit from surgeon.

GoalAssess the safety and efficacy of LVRS in comparison with medical therapy in patients with moderate to severe emphysema

J Thorac cardiovasc surg 1999; 118:518 - 28

Page 11: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

LVRSSelection of Patients

• COPD with emphysema with severe irreversible obstruction to airflow

• marked hyperinflation of the lung

• impaired exercise performance

• FEV1 < 35 % pred.

• TLC > 110 % pred. RV > 200%

• 12' walking < 600 m

• hypercapnia• pulmonary hypertension• "destroyed lung"

• paCO2 > 55 mm Hg• PAPm > 35 mm Hg

• DLCO < 20 %

Pulmonary Function≤ 45 %

> 100 %> 150%

6' w < 140 m

NETTZH

--------> 35 mm Hg--------

Page 12: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Patients at high risk of death after

lung volume reduction surgeryNational Emphysema Treatment Trial Research Group

FEV1 < 20 % pred. and homogeneous distribution of emphysema or DLCO < 20 % pred.

N Engl J Med, Vol. 345, No. 15 – Okt. 11, 2001

Page 13: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Improvement in Quality of Life from the NETT

All patients

upper lobe+ high ex

Ann Thorac Surg 2006;82:431-43

upper lobe+ low ex

Page 14: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Survival LVRS vs Medical Therapy from the NETT

All patients

upper lobe+ low ex

upper lobe+ high ex

Ann Thorac Surg 2006;82:431-43

Page 15: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Improvement in Quality of Life from the NETT

Non upper lobe+ high ex

Non upper lobe+ low ex

Ann Thorac Surg 2006;82:431-43

Page 16: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Conclusion from the NETT

The NETT has established and demonstrated the value of LVRS in

a specific group of patients suffering from emphysema

Claude Lenfantformer director, Nat. Heart, Lung and Blood Institut NIH

Ann Thorac Surg 2006;82:385-7

Page 17: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Weder et al. Ann Thorac Surg 1997

Morphologymarkedly

heterogeneousintermediatelyheterogeneous

homogeneous

Page 18: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

LVRV Effect on MRC

* = p < 0.05

* * * * * *

* * * ** * *

Weder Ann Thorac Surg. 2009

* = p < 0.05

Page 19: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

LVRS Effect on FEV1 %

* * * *

* *

*

* *

* = p < 0.05

* = p < 0.05 Weder Ann Thorac Surg. 2009

Page 20: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Transplantationfree survival according to emphysema

morphology

Hazard Ratio: 0.80, 95% CI 0.66 - 0.98, p = 0.03

0 20 40 60 80 100 120 140 160

Months

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

Cu

mu

lati

ve P

rop

ort

ion

Su

rviv

ing

non- heterogeneous

heterogeneous

Weder Ann Thorac Surg. 2009

Page 21: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Effect of LVRS on COPD exacerbation

Washko, AJRCCM 2007

Page 22: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Effect of LVRS on COPD exacerbation

Washko, AJRCCM 2007

Page 23: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Effect of LVRS on pulmonary hemodynamics

• In comparison to medical therapy, LVRS was not associated with an increase in PA pressure

Criner, AJ RCCM, 2007

• LVRS did not change pulmonary hemodynamics significantly

Thurnheer, EJ CTS 1998

Page 24: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Change in end-expiratory pulmonary capillary wedge

pressure

Criner, AJRCCM 2007

Page 25: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Before the NETT

LVRS improves dyspnea, pulmonary function work of breathing and quality of life in selected patients

After the NETT

Additionally it improves survival, COPD exa-cerbations and PCWP compared to medicaltreatment

Page 26: 13. Annual Congress Turkish Thoracic Society 5. – 9. May 2010, Istanbul

Patient selection for LVRS

The goodSymptomatic patient with marked hyperinflation, marked heterogeneity, upper lobe disease, DLCO > 20%

The badFEV1 < 20%, DLCO < 20%, homogenous disease

The uncertainMarked hyperinflation, non-marked heterogeneity, DLCO > 20%